Lazcluze Tablet, Film Coated
NDC Package 57894-080-90
Package Information
Lazcluze (lazertinib) tablets is lAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Janssen Biotech, Inc., this product is identified by NDC 57894-080 and is authorized under FDA application NDA219008.
Identification & Billing
- RxCUI: 2691156 - lazertinib 80 MG Oral Tablet
- RxCUI: 2691156 - lazertinib 80 MG (equivalent to lazertinib mesylate 93.86 MG) Oral Tablet
- RxCUI: 2691162 - Lazcluze 80 MG Oral Tablet
- RxCUI: 2691162 - lazertinib 80 MG Oral Tablet [Lazcluze]
- RxCUI: 2691162 - Lazcluze 80 MG (equivalent to lazertinib mesylate 93.86 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57894 - Janssen Biotech, Inc.
- 57894-080 - Lazcluze
- 57894-080-90 - 1 BOTTLE in 1 CARTON / 90 TABLET, FILM COATED in 1 BOTTLE
- 57894-080 - Lazcluze
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (57894-080). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57894-080-90 identifies a specific commercial package of 1 bottle in 1 carton / 90 tablet, film coated in 1 bottle of Lazcluze, a human prescription drug labeled by Janssen Biotech, Inc.. This tablet, film coated is formulated for oral use and contains lazertinib as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Janssen Biotech, Inc. on August 20, 2024. The current certification is valid through December 31, 2027.
How is this Janssen Biotech, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57894008090. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.